» Articles » PMID: 10606629

Altered Responsiveness to Chemokines Due to Targeted Disruption of SHIP

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1999 Dec 22
PMID 10606629
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

SHIP has been implicated in negative signaling in a number of hematopoietic cell types and is postulated to downregulate phosphatidylinositol-3-kinase- (PI-3K-) initiated events in diverse receptor signaling pathways. Because PI-3K is implicated in chemokine signaling, we investigated whether SHIP plays any role in cellular responses to chemokines. We found that a number of immature and mature hematopoietic cells from SHIP-deficient mice manifested enhanced directional migration (chemotaxis) in response to the chemokines stromal cell-derived factor-1 (SDF-1) and B-lymphocyte chemoattractant (BLC). SHIP(-/-) cells were also more active in calcium influx and actin polymerization in response to SDF-1. However, colony formation by SHIP-deficient hematopoietic progenitor cell (HPCs) was not inhibited by 13 myelosuppressive chemokines that normally inhibit proliferation of HPCs. These altered biologic activities of chemokines on SHIP-deficient cells are not caused by simple modulation of chemokine receptor expression in SHIP-deficient mice, implicating SHIP in the modulation of chemokine-induced signaling and downstream effects.

Citing Articles

CXCL15/Lungkine has suppressive activity on proliferation and expansion of multi-potential, erythroid, granulocyte and macrophage progenitors in S-phase specific manner.

Broxmeyer H, Cooper S, Ropa J Blood Cells Mol Dis. 2021; 91:102594.

PMID: 34520986 PMC: 9231597. DOI: 10.1016/j.bcmd.2021.102594.


Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26.

Broxmeyer H, Capitano M, Campbell T, Hangoc G, Cooper S Stem Cells Dev. 2016; 25(8):575-85.

PMID: 26943017 PMC: 4834524. DOI: 10.1089/scd.2016.0026.


SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.

Hamilton M, Halvorsen E, LePard N, Bosiljcic M, Ho V, Lam V Oncotarget. 2015; 7(4):3677-91.

PMID: 26683227 PMC: 4826161. DOI: 10.18632/oncotarget.6611.


CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

de Lourdes Perim A, Amarante M, Guembarovski R, Oliveira C, Watanabe M Cell Mol Life Sci. 2015; 72(9):1715-23.

PMID: 25572297 PMC: 11113340. DOI: 10.1007/s00018-014-1830-x.


SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging.

Iyer S, Brooks R, Gumbleton M, Kerr W Stem Cells Dev. 2014; 24(9):1073-81.

PMID: 25525673 PMC: 4403265. DOI: 10.1089/scd.2014.0501.


References
1.
Ganju R, Brubaker S, Meyer J, Dutt P, Yang Y, Qin S . The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998; 273(36):23169-75. DOI: 10.1074/jbc.273.36.23169. View

2.
Helgason C, Damen J, Rosten P, Grewal R, Sorensen P, Chappel S . Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998; 12(11):1610-20. PMC: 316868. DOI: 10.1101/gad.12.11.1610. View

3.
Kim C, Broxmeyer H . SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation. J Leukoc Biol. 1999; 66(3):455-61. DOI: 10.1002/jlb.66.3.455. View

4.
Osborne M, Zenner G, Lubinus M, Zhang X, Songyang Z, Cantley L . The inositol 5'-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation. J Biol Chem. 1996; 271(46):29271-8. DOI: 10.1074/jbc.271.46.29271. View

5.
Kim C, Pelus L, White J, Broxmeyer H . Macrophage-inflammatory protein-3 beta/EBI1-ligand chemokine/CK beta-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. J Immunol. 1998; 161(5):2580-5. View